# Merck KGaA (EMD Serono)

Source: https://onco.cc/companies/merck-kgaa/  
OnCo record `merck-kgaa` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Merck KGaA of Darmstadt, which trades as EMD Serono in North America, sells the anti-PD-L1 antibody avelumab, cetuximab outside the United States and the MET inhibitor tepotinib, and bought SpringWorks Therapeutics in 2025 to add nirogacestat and mirdametinib for rare tumours.

## Summary

Merck KGaA, the Darmstadt science and technology company that is distinct from the US Merck & Co., runs its healthcare business as EMD Serono in the United States and Canada. Its oncology medicines include avelumab (Bavencio), an anti-PD-L1 antibody used as maintenance in urothelial cancer and in Merkel cell carcinoma; cetuximab (Erbitux), which it markets outside North America; and tepotinib (Tepmetko) for MET exon 14-skipping non-small-cell lung cancer. In 2025 it acquired SpringWorks Therapeutics, bringing the gamma-secretase inhibitor nirogacestat for desmoid tumours and the MEK inhibitor mirdametinib for neurofibromatosis-related plexiform neurofibromas. Company facts are from FDA approval records and the SpringWorks acquisition announcement.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: EMD Serono; EMD Serono, Inc.; EMD Serono Research & Development Institute, Inc.; Merck Healthcare KGaA; Merck KGaA, Darmstadt, Germany; Merck Serono
- Tags: fda-oce-applicant
- HQ: Darmstadt
- Type: pharma
- Website: https://www.merckgroup.com

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Merck_Group
- FDA: oncology and hematologic malignancies approval notifications: https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Desmoid tumour](https://onco.cc/cancers/desmoid-tumour/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Merkel cell carcinoma](https://onco.cc/cancers/merkel-cell-carcinoma/), [MET exon 14 and MET-amplified non-small-cell lung cancer](https://onco.cc/cancers/met-altered-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Avelumab](https://onco.cc/drugs/avelumab/), [Capmatinib & tepotinib](https://onco.cc/drugs/capmatinib-tepotinib/), [Cetuximab](https://onco.cc/drugs/cetuximab/), [Mirdametinib](https://onco.cc/drugs/mirdametinib/), [Nirogacestat](https://onco.cc/drugs/nirogacestat/), [Precemtabart tocentecan](https://onco.cc/drugs/precemtabart-tocentecan/), [Tepotinib](https://onco.cc/drugs/tepotinib/), [Xevinapant](https://onco.cc/drugs/xevinapant/)
- companies: [Abbisko Therapeutics](https://onco.cc/companies/abbisko/), [SpringWorks Therapeutics (Merck KGaA)](https://onco.cc/companies/springworks/), [Threshold Pharmaceuticals](https://onco.cc/companies/threshold-pharmaceuticals/)
- trials: [A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)](https://onco.cc/trials/nct07170644/), [A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)](https://onco.cc/trials/proceade-crc-03/), [A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)](https://onco.cc/trials/nct05327530/), [Avelumab Program Rollover Study](https://onco.cc/trials/nct03815643/), [Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients](https://onco.cc/trials/nct07004413/), [EXTREME](https://onco.cc/trials/extreme/), [JAVELIN Bladder 100](https://onco.cc/trials/javelin-bladder-100/), [JAVELIN Head and Neck 100](https://onco.cc/trials/javelin-hn-100/), [OPUS](https://onco.cc/trials/opus/), [Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)](https://onco.cc/trials/nct06710132/), [Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)](https://onco.cc/trials/nct07499362/), [VISION (tepotinib)](https://onco.cc/trials/nct02864992/)
- technologies: [Downstream purification (Protein A capture, viral clearance, polishing)](https://onco.cc/technologies/downstream-purification-chromatography/), [Single-use bioprocessing systems](https://onco.cc/technologies/single-use-bioprocessing/), [The ADC supply chain (antibody, payload-linker, conjugation, fill)](https://onco.cc/technologies/adc-supply-chain/)

---
JSON: https://onco.cc/api/v1/entities/merck-kgaa.json